Technical Analysis for PDSB - PDS Biotechnology Corporation

Grade Last Price % Change Price Change
grade F 6.51 1.40% 0.09
PDSB closed up 1.4 percent on Friday, May 24, 2019, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical PDSB trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 1.40%
Calm After Storm Range Contraction 1.40%
Narrow Range Bar Range Contraction 1.40%

Older signals for PDSB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
Medicine Cancer Clinical Medicine Immunotherapy Oncology Cancers Prostate Cancer Breast Cancer Cancer Immunotherapy Melanoma Immunotherapies Head And Neck Cancer Oncolytics Biotech Cervical Cancer Anal Cancer Breast Cancers Northwest Biotherapeutics Treatment Of Melanoma
Is PDSB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 25.4
52 Week Low 5.03
Average Volume 184,712
200-Day Moving Average 11.1865
50-Day Moving Average 6.9832
20-Day Moving Average 6.5252
10-Day Moving Average 6.879
Average True Range 0.796
ADX 23.24
+DI 26.2279
-DI 17.8162
Chandelier Exit (Long, 3 ATRs ) 7.061999999999999
Chandelier Exit (Short, 3 ATRs ) 7.728
Upper Bollinger Band 7.9067
Lower Bollinger Band 5.1437
Percent B (%b) 0.49
BandWidth 42.34353
MACD Line -0.0199
MACD Signal Line -0.0413
MACD Histogram 0.0213
Fundamentals Value
Market Cap 200.84 Million
Num Shares 30.9 Million
EPS -1.57
Price-to-Earnings (P/E) Ratio -4.15
Price-to-Sales 0.00
Price-to-Book 3.94
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.81
Resistance 3 (R3) 6.79 6.67 6.76
Resistance 2 (R2) 6.67 6.59 6.68 6.74
Resistance 1 (R1) 6.59 6.55 6.63 6.61 6.73
Pivot Point 6.47 6.47 6.49 6.48 6.47
Support 1 (S1) 6.39 6.39 6.43 6.41 6.29
Support 2 (S2) 6.27 6.35 6.28 6.28
Support 3 (S3) 6.19 6.27 6.26
Support 4 (S4) 6.21